<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122832">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079272</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00929-36</org_study_id>
    <nct_id>NCT02079272</nct_id>
  </id_info>
  <brief_title>REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)</brief_title>
  <acronym>REBECCA</acronym>
  <official_title>REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity): Evaluation of Radiation-induced Cardiotoxicity of Adjuvant Radiotherapy With Tomotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophie JACOB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Radioprotection et de Surete Nucleaire</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a new technique of radiotherapy for breast
      cancer (helical tomotherapy) can induce cardiac toxicity that would be detected in the first
      two years after treatment. Screening of subclinical cardiac lesions with non-invasive
      cardiac imaging techniques combined with measures of circulating biomarkers of cardiac
      tissue lesions and coronary lesions would allow assessing radiation-induced cardiac toxicity
      at an early stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REBECCA study will consist in a monocentric prospective cohort that will include 120 women
      volunteers treated with adjuvant tomotherapy for breast cancer in the Institut Regaud
      Claudius-Toulouse (ICR) and followed for 2 years after radiotherapy.

      In summary, women aged between 40 and 70 years, surgically treated at ICR for breast cancer
      and for whom adjuvant radiotherapy with tomotherapy is indicated, with no indication of
      chemotherapy will be eligible for the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Number of participants with subclinical cardiac lesions in myocardial levels and/or coronary levels</measure>
    <time_frame>within the first 2 years after tomotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is defined as a decrease of at least 5% in strain or strain rate measures based on cardiac ultrasound exam&quot;2D strain&quot; between the measurement before radiotherapy and measures 24 months after radiotherapy and / or an increase of at least 15% in the average index of coronary plaques measured with CT coronary angiogram between the measurement before radiotherapy and measures 24 months after radiotherapy .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decrease in myocardial contractility (strain or strain rate measured with cardiac ultrasound exam&quot;2D strain&quot;)</measure>
    <time_frame>within the first 6 months after tomotherapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with modified measures of circulating biomarkers</measure>
    <time_frame>within the first 2 years after tomotherapy (at the end of radiotherapy, 6 months after radiotherapy and 24 months maximum after radiotherapy)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Toxicity Due to Radiotherapy</condition>
  <condition>Breast Cancer</condition>
  <condition>Lesion; Cardiac</condition>
  <arm_group>
    <arm_group_label>Helical tomotherapy for breast cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.
Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Helical tomotherapy for breast cancer</intervention_name>
    <description>At baseline, before helical tomotherapy is performed, for each included woman will have:
measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)
cardiologic examination including echocardiography for measurement of strain and strain rate
a CT coronary angiogram for measurement of coronary plaque indexes
Helical tomotherapy will be performed for all women included in the cohort.
At the end of tomotherapy, follow-up will include:
measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy
cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy
A CT coronary angiogram 24 months after radiotherapy</description>
    <arm_group_label>Helical tomotherapy for breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women treated surgically for left or right breast cancer and for who adjuvant
             treatment is radiotherapy with irradiation of the breast or chest wall irradiation
             and possibly lymph node chains,

          -  Age between 40 and 70 years

          -  Adjuvant Radiotherapy is helical tomotherapy performed at Institut Claudius
             Regaud(Toulouse, France)

        Exclusion Criteria:

          -  Indication of adjuvant chemotherapy

          -  Clinically or radiologically detectable metastasis

          -  Personal history of coronary artery or myocardial disease

          -  Personal history of breast cancer or other cancer requiring radiotherapy to the chest

          -  Contraindications to injection of iodinated contrast ( for CT ) : pregnancy , renal
             failure, allergy.

          -  Pregnancy, lactation

          -  Before radiotherapy, LVEF &lt;50%

          -  Before radiotherapy, longitudinal strain &gt; - 16 %

          -  Before radiotherapy,longitudinal strain rate &lt;1% / s

          -  Before radiotherapy, segmental wall motion abnormality

          -  Coronary CT before radiotherapy showing that a therapeutic treatment is required
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole Massabeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud, Toulouse (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Odile Bernier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Radioprotection et de Sureté Nucléaire, Fontenay-aux-Roses (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Ferrières, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rangueil, Toulouse (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Rousseau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rangueil, Toulouse (France)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Jacob, PhD</last_name>
    <email>sophie.jacob@irsn.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole Massabeau, MD</last_name>
    <email>Massabeau.Carole@claudiusregaud.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole Massabeau, MD</last_name>
      <email>Massabeau.Carole@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Carole Massabeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francoise Izar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte De Lafontan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Radioprotection et de Surete Nucleaire</investigator_affiliation>
    <investigator_full_name>Sophie JACOB</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Tomotherapy</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Heart</keyword>
  <keyword>Subclinical cardiac lesions</keyword>
  <keyword>Myocardial lesions</keyword>
  <keyword>Coronary lesions</keyword>
  <keyword>Circulating biomarkers</keyword>
  <keyword>Ionizing radiation</keyword>
  <keyword>Heart absorbed doses</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
